IBI-333

N/A

Report date: 2023/12/08 14:32:27

Base Information

Drug NameIBI-333

Drug Alias NameIBI-333

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionVascular endothelial growth factor A inhibitorsVascular endothelial growth factor C inhibitors

TargetsVascular endothelial growth factor CVascular endothelial growth factor A

Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInnovent Biologics (Usa), Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsWet age-related macular degenerationMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A